Chicago Clinical Trials Unit

描述(由申请者提供)：芝加哥临床试验单位(CCTU)是由五个临床研究网站(CRSS)组成的联合体，将致力于NIAID的三个优先临床研究领域：1)成人艾滋病毒治疗策略，包括艾滋病毒治愈、非传染性并存以及肝炎和结核病的传染性并存；2)预防艾滋病毒的疫苗；3)艾滋病毒的综合预防策略。CCTU由五个经验丰富、科学成果丰富的CRSS组成，它们在开发、实施和调整NIAID临床研究优先领域的临床研究优先事项方面具有独特的地位。 CCTU拥有良好的业绩记录，并将通过积极参与各种高危和受艾滋病毒影响的社区、参与高影响力的突破性临床研究、有效管理资源和对临床活动、实验室和药店进行关键绩效监督来继续提高生产率。CCTU包括CRSS和与其中三个研究网络有长期和富有成效的参与的人员；第四个研究网络-抗菌素耐药性-是该联盟中的一个新网络。CRSS及其网络附属机构包括：西北大学(成人艾滋病毒治疗战略)；伊利诺伊芝加哥大学(预防艾滋病毒的疫苗，综合艾滋病毒预防)。拉什大学(成人艾滋病毒治疗战略)、芝加哥大学(综合艾滋病毒预防战略)和三一健康与健康中心(成人艾滋病毒治疗战略)。其中四个CRSS位于芝加哥，这是一个拥有950万人口的种族和种族多元化的城市地区，是美国第三大大都市区，也是主要的城市艾滋病毒中心之一。这项建议的目标是：1)成人艾滋病毒治疗战略网络的临床研究计划的制定、实施和调整，2)预防艾滋病毒的疫苗网络，3)综合艾滋病毒预防战略网络，以及4)相关和高危艾滋病毒感染者/受影响社区与CCTU临床研究人员的双向接触。CCTU处于有利地位，可以接触到不同的人群，并为NIAID的研究议程做出重大贡献。 相关性：在过去30年中，艾滋病毒/艾滋病研究取得了惊人的科学进步，这在很大程度上是由于NIAID的临床试验单位(CTU)正在进行的高影响力的治疗和预防研究。芝加哥CTU将继续对新出现的临床研究需求做出快速反应，吸引参与者，并确定更有效的治疗和预防策略。

DESCRIPTION (provided by applicant): The Chicago Clinical Trials Unit (CCTU) is a consortium of five Clinical Research Sites (CRSs) which will address three priority clinical research areas of the NIAID: 1) adult HIV therapeutic strategies including HIV cure, noninfectious comorbidities, and infectious co-morbidities of hepatitis and tuberculosis; 2) vaccines to prevent HIV; and 3) integrated HIV prevention strategies. The CCTU consists of five highly experienced and scientifically productive CRSs that are uniquely positioned to develop, implement and adapt the clinical research priorities of the NIAID clinical research priority areas. The CCTU has a proven track record and will continue its productivity through active engagement with a diverse host of at risk and HIV-impacted communities, participation in high impact, ground-breaking clinical research studies, efficient management of resources and critical performance oversight of the clinical activities, laboratories, and pharmacies. The CCTU includes CRSs and personnel that have long term and productive involvement with three of the research networks; the fourth-antibacterial resistance-being a new network in this consortium. The CRSs and their network affiliations include: Northwestern University (adult HIV therapeutic strategies); University of Illinois Chicago (vaccines to prevent HIV, integrated HIV prevention). Rush University (adult HIV therapeutic strategies), University of Chicago (integrated HIV prevention strategies) and Trinity Health & Wellness Center (adult HIV therapeutic strategies). Four of the CRSs are located in Chicago, an ethnically and racially diverse urban area of 9.5 million persons that is the third largest metropolitan region in the United States and one of the major urban HIV epicenters. The aims of this proposal are: development, implementation and adaptation of the clinical research program of the 1) Adult HIV Therapeutics Strategy, Network, 2) the Vaccines to Prevent HIV Network, 3) the Integrated HIV Prevention Strategies Network, and 4) Bidirectional, engagement of the relevant and at risk HIV-infected/impacted communities with the CCTU clinical researchers. The CCTU is well positioned to reach diverse populations and contribute significantly to the NIAID research agenda. RELEVANCE: The phenomenal scientific advances in HIV/AIDS research over the past 30 years have in large part been due to NIAID's high-impact therapeutic and prevention studies being performed by its clinical trials units (CTUs). The Chicago CTU will continue to respond rapidly to emerging clinical research needs, engage constituents, and identify more effective treatment and prevention strategies.